Pharma Mar (NASDAQ:PHMMF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain. “

Shares of Pharma Mar (NASDAQ:PHMMF) opened at 4.2753 on Friday. Pharma Mar has a one year low of $2.40 and a one year high of $4.80. The stock’s market capitalization is $1.06 billion. The firm’s 50-day moving average price is $4.44 and its 200-day moving average price is $4.06.

COPYRIGHT VIOLATION NOTICE: “Pharma Mar (PHMMF) Downgraded by Zacks Investment Research to “Hold”” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at

Get a free copy of the Zacks research report on Pharma Mar (PHMMF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with's FREE daily email newsletter.